Individuals with higher TSHI and TT4RI, reflecting reduced central thyroid hormone sensitivity, had significantly increased ...

A recent study published in The New England Journal of Medicine has found that elinzanetant, a therapy targeted at neurokinin ...

As recommendations suggest extending hormone-based breast cancer treatment to 10 years for some patients, a new study sheds ...

For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive ...

More than 46% of women with stage 1 or 2 breast cancer chose to continue endocrine therapy after five years, a recent study found. The study, published in the Journal of the National Cancer Institute, ...

Highlights from the 2025 Global Equine Endocrinology Symposium included never-before-presented study results on insulin ...

Leukemia findings are especially striking – potentially lending support to plaintiffs in court cases who allege that Roundup ...

As recommendations suggest extending hormone-based breast cancer treatment to 10 years for some patients, a new study sheds light on whether patients are opting for it.

CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women ...

The following is a summary of “Oral semaglutide for the treatment of obesity: a retrospective real-world study,” published in ...

Telemedicine helped increase access to endocrinology care for adults with type 2 diabetes and atherosclerotic cardiovascular disease living in rural areas, but several disparities remain, researchers ...

The study, which was published in the journal eBioMedicine, linked a specific type of phthalate called ...